While there is little doubt that Graves' ophthalmopathy is an autoimmune disease, the nature of the disordered immune response still eludes our understanding. This is largely because the target of attack, the retroocular/bulbar tissue, is unaccessible to research workers and, also, there is no suitable animal model with which to pursue hypotheses. The much greater appreciation we have of thyroid autoimmunity indicates the importance of these two desiderata. Despite these problems, however, there has been renewed immunological interest in Graves' ophthalmopathy, with the appreciation that a greater knowledge of the pathogenesis should permit both prediction of the course of disease and improve its treatment. The early observations on autoimmunity in ophthalmopathy have been considered in detail by several authors'-3 and the present review will focus particularly on recent immunological advances, after a brief consideration of the relationship between thyroid disease and ophthalmopathy.
Thyroid and eye disease: independent pathogensis? A recurring motif in thyroid eye disease concerns the question of whether Graves' thyrotoxicosis and ophthalmopathy share the same immunopathogenesis, or instead are two closely related but independent entities. In favour of the first of these alternatives is the very close association ofthe two conditions. Indeed 40-90% of Graves' disease patients with no evidence of ophthalmopathy can be shown to have eye muscle disease using techniques such as exophthalm-ometry4, ultrasonography5, computerized tomographic scanning6 and evaluation of saccadic eye movement fatigue7. Moreover, an abnormal increase in intraocular pressure between resting and upward gaze was found in over 75% of Graves' disease patients8, taken to indicate inflammation and fibrosis of the inferior recti, but others have failed to confirm these results9.
Together these studies certainly show a high frequency of clinically silent ophthalmopathy in Graves' disease, but also suggest that the two conditions are not inextricably linked. Moreover ophthalmopathy occurs, albeit rarely, in Hashimoto's thyroiditis or even in the absence of thyroid disease; so called ophthalmic Graves' disease'0. Treatment of Graves' hyperthyroidism has no consistent or major effect on the eye disease, although the progression of disease may be slightly slowed by surgery or radioiodine and enhanced by propylthiouracil", and patients may develop eye disease when euthyroid. Ifthese two conditions shared a common pathogenesis a more obvious relationship with thyroid treatment would be expected, given the marked immunological sequelae of all three forms of therapy'2. More evidence in favour of an independent aetiology comes from some reports showing differences in genetic susceptibility (considered below) and the less obvious female preponderance in ophthalmbopathy compared to hyperthyroid Graves' disease. The recent demonstration of an association between smoking and severe ophthalmopathy suggests one mechanism for this altered sex ratio'3.
It seems likely, therefore, that ophthalmopathy is an independent autoimmune disorder which is closely associated with thyroid autoimmunity, and Graves' disease in particular. The immunological links between the two disorders are not clear, although an effect ofTSH or TSH receptor antibodies on the orbit seems unlikely'4. The possibility of other shared autoantigenic determinants triggering an autoimmune response to both thyroid and orbit could explain the link. Alternatively genetic susceptibility or environmental factors could be common to both conditions. However, there are sufficient grounds for believing that at least some of the immunopathogenic mechanlisms operating in ophthalmopathy are unique to this disease.
Orbital pathology in Graves' ophthalmopathy Characterization ofthe inflammatory infiltrate using techniques such as immunohistochemical identification of lymphocyte subsets and in vitro tests of antigenic reactivity have not been performed, due to the lack of readily available material, so our knowledge of orbital pathology is presently limited to morphological observations. It seems certain that the primary site of involvement is the extraocular muscle; all muscles are affected although to varying degrees'5"16. The initial infiltrate is both focal and diffuse, and composed mainly of lymphocytes ( Figure 1A ). Later fibroblasts enlarge and proliferate and at this stage muscle oedema is found, related to increased mucin production by fibroblasts. Finally the muscle becomes fibrosed and the fibres atrophy: all muscle changes appear entirely related to this fibrosis. A similar sequence ofchanges can occur in the lacimal glands ( Figure 1B) .
The orbital fat rarely shows inflammatory changes'5 and we have found only a single, small focus of lymphocytes in extensive sectioning of three specimens of orbital connective tissue from patients with severe Graves' ophthalmopathy. Prominent extraocular muscle infiltration with fat has been described in some cases'7 but appears to be less obvious in other specimens'5"6.
While the extraocular muscles are a key target for lymphocytic infiltration in ophthalmopathy, the pathological features do not provide striking support for primary muscle destruction by the infiltrate as a Paper read to Section of Ophthalmology, 12 November 1987 0141-0768/89/ 030153-06/$02.00/0 O 1989 The Royal Society of Medicine Figure 1 . A, prominent focal and diffuse lymnphocytic infiltration ofextraocular muscle in Graves' ophthalmopathy. B, lymphocytic infiltration in the lacrimal gland in Graves' ophthalmopathy (magnificationx400) major mechanism in producing dysfunction, and although lymphocytes may occasionally be seen cuffing degenerating muscle fibres15, this is quite rare in our experience. Instead it seems that the inflammation is accompanied by marked oedema, probably related to the production of mucopolysaccharides by stimulated fibroblasts.
As long ago as 1972, it was suggested that lymphocytes directly stimulate retrobulbar. fibroblasts in vitro to secrete glycosaminoglycans18. This activity is most likely to be due to the secretion of lymphokines like transforming growth factor -fl, a product of activated T lymphocytes (and macrophages) which is known to stimulate fibroblasts'9. An issue which must now be addressed concerns the reason for the localization of pathology to the eye muscle. Is this related to some mechanism whereby lymphocytes preferentially home on to the eye muscles (although infiltrates can also be found in the skeletal muscle in some patients with Graves' disease20) or are the retrobulbar fibroblasts uniquely sensitive to lymphokines?
Cellular immunity in ophthalmopathy T cell reactivity to orbital antigens in patients with
Graves' ophthalmopathy has been assessed using several types of assay (Table 1 ) and peripheral blood lymphocytes; clearly these circulating cells may only reflect partially (if at all) the responses of T cells in the eye muscles. In the first such study, a crude preparation of retrobulbar connective tissue elicited production of the lymphokine, migration inhibition factor (MIF), in 9 of 10 patients with ophthalmopathy and 6 of 10 patients with Graves' disease with no orbital involvement'2.
Possibly more relevant, given the pathological features, was the demonstration of MIF production in respone to an unidentified retroocular/bulbar muscle antigen by all of 15 patients with exophthalmos22. Surprisingly, the MIF response of T cells to thyroid antigens in this study correlated quite well with an increase in non-immune rosette forming cells, a finding which was later retracted23. Moreover, these early studies with crude preparations give little indication of which antigen the T cells respond to.
Partial purification of a retroocular/bulbar antigen (from pooled eye muscle fat and lacrimal gland) suggested that thyroglobulin (Tg) or some component of Tg was responsible for the positive MIF test24.
Certainly there have been repeated suggestions that Tg may localize to eye muscle, and interaction with Tg antibodies or Tg-reactive T cells could then play a role in pathogenesis25,26. However, if this is so, it is difficult to see why Graves' ophthalmopathy is so rare in Hashimoto's thyroiditis, which is usually accompanied by high levels of Tg antibodies and Tgreactive T cells. In contrast to these positive findings, MIF production in response to a lacrimal gland extract or to a mixed antigen preparation of retrobulbar connective tissue, muscle and optic nerve could not be demonstrated in other studies of patients with ophthalmopathy27,28, so that a firm conclusion on T cell sensitization as demonstrated by this assay cannot be made.
Because the MIF test is rather cumbersome, as well as giving discordant results, other assays for T cell function have been used. The leucocyte adherence inhibition assay, (which may also reflect the presence of cytophilic antibodies), was positive in only 2 of 15 Lymphocytes (L) sensitized to an antigen release procoagulant 30 activity (PCA). which is assayed by measuring clot formation time fQr recalcified citrated plasma ophthalmopathy patients and one of 15 controls using eye muscle antigen29. A lacrimal gland extract produced a positive blastogenic response in nine of 22 patients; clinical evidence of lacrimal gland involvement was not recorded in these subjects27. The ability of eye muscle to stimulate T cell proliferation does not seem to have been assessed. More recently a test for release of leucocyte procoagulant activity (LPCA) by T cells has been used to delineate T cell sensitization30. Two-thirds of ophthalmopathy patients gave positive LPCA responses when lymphocytes were cultured with eye muscle cytosol; less than a third responded to an orbital connective tissue preparation. The inconsistencies between these tests of T cell function may reflect different sensitivities or the involvement of complex interactions perhaps favoured in some particular types of assay.
There have also been recent attempts to identify cell-medicated cytotoxicity towards eye muscle. In a single patient with ophthalmopathy, circulating lymphocytes were cytotoxic to cultured eye, but not thigh, muscle cells from an unrelated donor31. Although of great interest, it is difficult to assess the nature of the lymphocyte subset responsible, since this cytQtoxicity was antigen-specific, unlike natural killer (NK) cell activity, and yet not restricted by major histocompatibility complex (MHC) genes (unlike T cell activity).
A more detailed study recently examined antibodydependent cell-mediated cytotoxicity (ADCC),ggainst eye muscle cells32. This form of cell killingis mediated by killer (K) cells, closely related to and probably a subset of NK cells. In ADCC a target cell antigen is bound by specific antibody and then the K cell lyses the target by interaction of the constant region fraction (Fc) portion of the antibody with. an Fc. receptor on the K cell. Specificity thus resides in the antibody. Significant ADCC was found using serum from 5 of 13 Graves' patients' ophthalmopathy. Since any source of K cells will effect AIDCC, this study used normal lymphocytes, but it is important to note that (i) the same study found decreased NK cell activity in ophthalmopathy patients, so that intrinsic K cell function may in fact differ between normals and patients, (ii) one normal source of K cells did not give significant results, (iii) the purity ofthe cultured eye muscle cells was not assessed, (iv) the sera giving positive ADCC failed to fix complement and (v) skeletal muscle failed to give a significant ADCC response. In a later study a close correlation was found between ADCC of eye and skeletal muscle when yinterferon ('y-IFN) was included in cultures;
unfortunately results for non--y-IFN-treated skeletal muscle were not given. There was also a lesser degree of ADCC towards orbital fibroblasts. The mechanism for enhanced cytotoxicity with 7y-IFN is not clear although this T cell-derived lymphokine is well known to stimulate NK cell function. -y-IFN predictably induced MHC class I and class Ilantigen expression on the target cells in these experiments but the relevance of this is uncertain since the level of class II antigen expression by eye muscles in ophthalmopathy is not known, and in any case these molecules play no part in ADCC. In summary, we still have a lot to learn about cellular immunity in ophthalmopathy. Given the infrequency and relative unimportance of lacrimal gland involvement, results of sensitization assays with this material are difficult to interpret. The nature ofthe extraocular muscle antigens recognized by T cells and by the antibodies in ADCC are so far unidentified, and it is unclear whether these are shared to any extent with skeletal muscle. Newer techniques, such as T cell cloning, could provide useful information to fill these gaps.
Humoral immunity in ophthalmopathy -The search. for circulating antibodies in ophthalmopathy has a long and confusing history. An early investigation failed to find significant antibodies against lacrimal gland, guineapig Harderian gland, orbital connective tissue or eye muscle antigens by haemagglutination or immunofluorescence34. Later the same group reported a high incidence (73%).ofeye muscle antibodies detectable by immunofluorescence in ophthalmopathy although reasons for this improvement were not discusSed35.
An alternative approach.in which monoclonal antibodies were raised against putative orbital antigens was more definitive; one such monoclonal was used to monitor.corresponding antigenic reactivity, so that partial purification of a soluble human eye muscle .antigen was achieved36. This preparation was used in an enzyme-linked immunosorbent assay (ELISA) in which 74% of ophthalmopathy patients had detectable antibodies, but none of 16 Graves' patients without clinical eye involvement reacted. Unfractionated antigen was contaminated with IgG, making any assay using this material impossible to interpret35.
However, porcine eye muscle is free of this problem and was used to detect antibodies against an ultracentrifuged (100 O0Og) muscle membrane preparation in an ELISA37. In this assay, 64% of active ophthalmopatly patients.were positive but again serum from only one of 22 thyroid disease patients without clinically evident eye disease reacted3. The assay was thought to be eye musclespecific since in establishing the assay no reactivity was detected with skeletal muscle or liver antigen37. Apparent confirmation ofthese results was provided using human eye muscle antigen and quantitating antibody binding with 125I protein A39.
However, several subsequent studies have failed to give such clear results4"43 and in particular it has become obvious that some eye muscle antibodies at least are not specific, since activity can be absorbed by skeletal or liver membranes42 and some antibodies bind to skeletal and thyroid antigens4l. Probable shared antigens accounting for this include actin tubulin and acetyl choline receptors43'". Further characterization of the original porcine eye muscle ELISA37 has confirmed these results45.
Another main area of investigation has been to establish whether Tg is present (or has a cross-reactive antigen) in orbital muscle. As mentioned previously, immunoreactive Tg-like material was reported in normal orbital muscle"'25 suggesting that this may provoke a common autoimmune.response in thyroid and eye disease. However, monoclonal'anti-Tg antibodies showed no reactivity with orbital muscle". It was later found that four of 16 such reagents bound to an insoluble membrane fraction of orbital connective tissue (unlikely to be Tg itself)"7. The reverse-approach yielded somewhat different results; immunization of mice with eye muscle membranes allowed the production of a monoclonal antibody which reacted with mammalian Tg48. However, a very low frequency of such hybridomas was reported, suggesting that the responsible epitope is uncommon in eye muscle.
Further impetus to identify Tg cross-reactivity in eye muscle came from the rather surprising homology demonstrated between residues in bovine Tg and Torpedo californica acetylcholinesterase (AChE)49 which led to the hypothesis that eye muscle AChE could cross-react with anti-Tg antibodies and produce ophthalmopathy5O. Support for this was provided by the correlation between enzyme-linked assays for anti-Tg and T. californica AChE binding reactivity using Graves' sera and in situ visualization of anti-Tg antibodies co-localizing with AChE-antibodies in fetal diaphragm51'52. However, once again the picture is less than clear, since antibodies to chick brain and human red blood cell AChE did not correlate with Tg reactivity53. Moreover, this hypothesis makes it difficult to explain why (i) ophthalmopathy shows no clinical association with the presence ofTg antibodies and (ii) eye muscle AChE alone should be so susceptible to an autoimmune response.
Two novel approaches are also noteworthy. Rotella and colleagues have shown that some monoclonal TSH receptor antibodies can increase collagen synthesis by normal skin fibroblasts and there was a striking correlation between the level of circulating antibodies with this activity and the severity of ophthalmopathy in Graves' disease". Bahn et aL cultured retroorbital fibroblasts to explore potential alterations in these cells in Graves' disease compared to normals55. They showed no source-dependent difference in the binding of putative autoantibodies which were found in 9 of 39 sera from Graves' ophthalmopathy patients, but strikingly found no antibody binding using skin fibroblasts.
To summarize this section, it seems difficult to claim any convincing demonstration of eye-muscle specific autoantibodies uniquely associated with ophthalmopathy. The inconsistencies in the data discussed are mainly rooted in species and methodological differences. In some ofthe discussion generated there has also been an inappropriate assumption that the mere presence of an antibody is pathogenic. Indeed, since many studies have only found antibodies in clinically obvious disease, and yet subelinical ophthalmopathy in Graves' disease is so common4-8, the presence of such antibodies could readily be argued to be merely a secondary phenomenon. Two key issues remain to be firmly clarified: (i) are there shared antigenic determinants between thyroid and eye; if so what are they and (ii) is any retroocular/bulbar tissue antigenically unique, so that the localization of disease can be explained? Until these questions are resolved, many others will remain unanswered, including whether non-specific muscle binding antibodies have any role in disease and whether skin fibroblasts can truly be used as a model for studying the effects of circulating thyroid/eye antibodies.
Immunogenetics
There has been considerable interest in examining the immunogenetic susceptibility to ophthalmopathy, which could be relevant in predicting the occurrence of disease, its outcome and relationship to Graves' hyperthyroidism. However, no clearly different HLA-DR association has been forthcoming in Caucasians, although there may be minor alterations of some antigens ( Table 2) . Recent attention has been directed to the MHC class I genes and some increase in HLA-BW35 and HLA.B8 has been reported in ophthalmopathy patients8-59'64.
Allotypic markers on IgG molecules, Gm allotypes, have been investigated as a second immunogenetic system which could be involved in susceptibility. There is no consensus regarding an association between Gm allotypes and Graves' thyroid disease65,W and there is a single report of an increased risk conferred by certain allotypes in ophthalmopathy, although this depended on an interaction with HLA-B8, and was not significant alone58. Investigation of immunoglobulin switch region polymorphisms (which are in linkage with Gm allotypes) by Southern blotfing showed no signifcantly abnormal distribution in ophthalmopathy patients62. Thus there are hints that some genes, possibly in the MHC class I region, may confer susceptibility for ophthalmopathy, although overall this condition in Caucasians shares the same rather weak association with HLA-DR3 that Graves' hyperthyroidism and many other organ-specific autoimmune conditions display. More refined multigene analysis at the molecular level should permit better characterization of patients in the near fuiture.
Conclusion
Taken together, the evidence now points overwhelmingly to autoimmunity as the cause ofophthalmopathy, although we are still ignorant oftriggering factors, the nature of the autoantigens involved and the important pathogenetic mechanisms. However, recent work has suggested several possibilities.
Smoking rves further invesigation as a triggering factor13, in particular into the effect of smoking via an action on the immune system. Sharing of autoantigens between the orbit and the thyroid is still possible and the cloning of antigens-should permit more sophisticated analysis of this: for instance, the relevance of Tg and AChE cross reactivityw5 would become clearer if human extra-ocular muscle AChE is sequenced. Molecular techniques should also allow characterization of other retrobulbar antigen so that any unique determinants present on fibroblasts can be characterized. It now seems less likely that eye muelespecific antibodies are of primary importance40u but antibodies cross-reacting with skeletal musc-le could be involved in pathogenesis, possibly by mediating ADCC3. Local release of lymphokines by infiltrating cells may also be very important, since these could produce many of the known patlhological features of the disease. Consolidation, and probably some alteration, ofthis picture are likely in the near future and this should improve treatment for ophthalmopathy by opening up the possibility of specific immunological intervention. 
